Torrent Pharma Q1 FY27 revenue climbs 55%; profit rises 3% amid JB Pharma costs
Torrent Pharma reported Q1 FY27 revenue of Rs 4,921 crore, up nearly 55% year on year, while EBITDA rose 61% to Rs 1,664 crore. Net profit increased 3% to Rs 566 crore after a Rs 21 crore one-time loss linked to the JB Pharma amalgamation. India revenue grew 19% to Rs 2,157 crore.
What happened
Torrent Pharmaceuticals · Torrent Pharma reported Q1 FY27 revenue growth of nearly 55% and EBITDA growth of 61%, while net profit rose 3% amid JB Pharma
Key facts
- Q1 FY27 consolidated net profit: Rs 566 crore, up 3% YoY
- Sequential net profit growth: 45% from Rs 389 crore
- One-time loss: Rs 21 crore
- Revenue from operations: Rs 4,921 crore, up nearly 55% YoY
- EBITDA: Rs 1,664 crore, up 61% YoY
- EBITDA margin: 33.8%, versus 32.5% in Q1 FY26
- India revenue: Rs 2,157 crore, up 19% YoY
- Brazil revenue: Rs 277 crore, up 27%
- US revenue: Rs 418 crore, up 36%
- Germany revenue: Rs 318 crore, up 3%
Why this matters
The JB Pharma deal is already expanding Torrent’s scale materially, with near-term integration charges likely outweighed by the strategic revenue and margin potential.
What to watch
- Quarterly India revenue growth versus the reported 19% pace.
- EBITDA margin movement after JB Pharma consolidation.
- Further exceptional, integration or financing costs tied to the amalgamation.
- Management disclosure on synergy run-rate, product rationalisation and debt reduction.
- Prescription-market-share trends in chronic therapies and channel inventory levels.
- Accelerate JB Pharma portfolio, manufacturing and sales-force integration.
- Rationalise overlapping brands and distributor/stockist networks while protecting prescription availability.
- Prioritise high-margin chronic therapies and cross-sell acquired brands through Torrent's India field force.
- Communicate a clearer timeline for cost synergies, exceptional-cost normalisation and deleveraging.